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In Minnesota, incidence of invasive group B streptococ-
cal disease was 3 times greater in older adults in long-term 
care  facilities  than  in  older  adults  in  community  settings 
(67.7/100,000  vs.  21.4/100,000)  during  2003–2007.  The 
overall case-fatality rate was 6.8%, and concurrent condi-
tions were common among both groups.
I
nvasive group B streptococcal (GBS) disease is a major 
cause of illness and death in older adults (1). A 2- to 
4-fold increase in invasive GBS disease among US adults 
has been reported since the 1980s (2), and incidence in-
creased 32% in adults from 1999 through 2005 (1). The 
objective of this study was to characterize the incidence 
and  epidemiology  of  GBS  disease  in  Minnesota  among 
the elderly in long-term care facilities (LTCFs) and in the   
community.
The Study
The Minnesota Department of Health conducts state-
wide,  population-based  surveillance  for  GBS  disease  as 
part of the Centers for Disease Control and Prevention Ac-
tive Bacterial Core Surveillance Network/Emerging Infec-
tions Program. Invasive disease is defined as isolation of 
GBS bacteria from a normally sterile site, such as blood, 
pleural fluid, cerebrospinal fluid, joint fluid, or bone (3). 
To ensure completeness of reporting, the Minnesota De-
partment of Health audits laboratories to identify all GBS 
bacteria–positive cultures from normally sterile sites. For 
each case, a standardized case report form is completed by 
hospital infection control practitioners. GBS isolates are 
sent to the Minnesota Department of Health Public Health 
Laboratory for susceptibility testing using broth microdi-
lution.  Erythromycin-resistant,  clindamycin-susceptible 
isolates are tested for inducible clindamycin resistance by 
double-disk diffusion (D test). Interpretation is based on 
Clinical and Laboratory and Standard Institute protocols 
(4).  Serotyping  is  performed  at  the  Centers  for  Disease 
Control and Prevention by latex agglutination tests with 
rabbit antiserum to GBS capsular polysaccharide types Ia, 
Ib, and II–VIII (5). When latex tests are indeterminate, the 
Lancefield method is used (6).
The study comprised all Minnesota residents aged >65 
years with invasive GBS disease during 2003–2007. LTCF 
residence was defined as living in an LTCF before the date 
of first positive culture. Resident addresses were checked 
by a reverse-address directory to determine whether they 
corresponded with the address of an LTCF. All other resi-
dents were defined as community dwelling. Incidence was 
calculated using 2000 census data. Analyses were conduct-
ed using SAS version 9.1 (SAS Institute, Cary, NC, USA); 
the χ2 test was used to evaluate differences in proportions 
for discrete variables.
A total of 723 cases of invasive GBS disease among 
persons >65 years of age were reported; 596 (82.4%) cases 
occurred among community residents, and 127 (17.6%) oc-
curred among LTCF residents (Table 1). The overall inci-
dence rate was 24.3 cases per 100,000 persons. Incidence 
did not vary significantly by year but did increase with age 
(19.3/100,000 at 65–74 years, 26.3/100,000 at 75–84 years, 
and 36.9/100,000 at >85 years; χ2 for trend = 44.4, p<0.001) 
and was higher among LTCF residents than among com-
munity residents (67.7/100,000 vs. 21.4/100,000; p<0.001). 
The overall case-fatality rate was 6.8 (8.7% LTCF vs. 6.4% 
community). Case-fatality rates increased as age increased 
(6.0% at 65–74 years, 6.8% at 75–84 years, and 8.2% at 
≥85 years).
The most common clinical presentation reported was 
bacteremia without focus (50.2%), followed by pneumo-
nia  (10.9%).  LTCF  residents  (18.9%)  were  more  likely 
than community residents (9.2%) to have pneumonia (p 
= 0.002) (Table 1). Blood (84.0%) was the most common 
site for isolation of GBS bacteria, followed by joint fluid 
(10.2%) and bone (3.3%). Other sites included peritoneal 
fluid (1.4%), pleural fluid (0.7%), and cerebrospinal fluid 
(0.4%).
Data on concurrent conditions were collected for 96 
(75.6%) of 127 LTCF case-patients and 448 (75.2%) of 
596 community case-patients. Of these, 176 (32.3%) had 
only 1 concurrent condition, 166 (30.5%) had 2 concurrent 
conditions, and 145 (26.6%) had >3 concurrent conditions. 
LTCF residents (94.8%) were more likely than community 
residents (88.4%) to have a documented concurrent condi-
tion (p = 0.06) (Table 1). Among case-patients with known 
concurrent condition status, 41% had diabetes mellitus and 
30% had coronary artery disease; similar proportions were 
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gestive heart failure (26.0% vs. 15.0%, p = 0.009), stroke 
(13.5% vs. 5.1%, p = 0.003), and chronic obstructive pul-
monary disease (15.6% vs. 8.3%, p = 0.026) were more 
common among LTCF residents. Cancer was more com-
mon among community residents (28.1% vs. 13.5%, p = 
0.003) (Table 1). Cellulitis as a manifestation of invasive 
GBS disease was more likely in residents with diabetes than 
in those without diabetes (24.4% vs. 16.3%, p = 0.019).
GBS serotypes were obtained for 654 (90.5%) of 723 
case-patients.  Five  serotypes,  Ia  (21.1%),  Ib  (11.0%)  II 
(11.8%), III (11.3%), and V (35.0%), accounted for 94.6% 
of  LTCF  case-patients  and  89.7%  of  community  case-
patients. Antimicrobial drug susceptibility data were ob-
tained for 655 (90.6%) of 723 case-patients. All isolates 
were susceptible to penicillin. Susceptibility to erythromy-
cin and clindamycin decreased during 2003–2007 (Table 
2). Sixty percent of erythromycin-resistant, clindamycin-
susceptible isolates had inducible clindamycin resistance 
as evidenced by a positive D test. During 2004–2005, 78% 
of erythromycin-resistant, clindamycin-susceptible isolates 
had inducible clindamycin resistance compared with 46% 
from 2006–2007 (p = 0.003). Serotype V was associated 
with higher rates of resistance than other serotypes to both 
erythromycin (46.7% vs. 27.9%, p<0.001) and clindamycin 
(28.4% vs. 12.9%, p<0.001). Serotype V was also associ-
ated with higher rates of inducible clindamycin resistance 
(88.6% vs. 43.4%, p<0.001).
Conclusions
We found that rates of invasive GBS disease were 
substantial among the elderly and 3× higher among LTCF 
residents than elderly persons living in the community. 
These  results  are  supported  by  an  earlier  report  from 
Maryland that also found increased incidence of invasive 
GBS infections in LTCF residents (7). The reason for in-
creased incidence in LTCF residents is not fully known. 
However, concurrent conditions, such as advanced age, 
diabetes, cirrhosis, and stroke, are known risk factors for 
GBS infection (8). In our study, concurrent conditions 
were common among both groups, however, concurrent 
condition types differed by group. Although higher rates 
of GBS disease among LTCF residents may be caused in 
part by differences in underlying concurrent conditions, 
other factors not collected as part of this study may also 
play a role. These factors include use of invasive devices 
(urinary catheters, intravenous catheters) and the possible 
role of person-to-person transmission of GBS bacteria in 
LTCF settings.
Case-fatality rates in this study were lower than those 
reported  in  other  studies.  National  surveillance  data  (1) 
have shown a case-fatality rate of 13.1% for persons >65 
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Table	1.	Comparison	of	LTCF	residents	and	community-dwelling	elderly	persons	with	invasive	GBS	disease,	Minnesota,	2003–2007*	
Characteristic LTCF elderly, no. (%) Community	elderly,	no.	(%)	
Total no. case-patients  127 596
Male gender  63	(49.6)	 338	(56.7)	
Type of infection†  63	(49.6)	 297	(49.8)	
  Bacteremia without focus  24	(18.9)	 55	(9.2)	
	 Pneumonia	 17 (13.4)  120 (20.1) 
	 Cellulitis	 5	(3.9)	 47	(7.9)	
	 Septic	arthritis	 5	(3.9)	 24 (4.0) 
  Osteomyelitis  6 (4.7)  20 (3.4) 
	 Abscess	 1 (0.8)  3	(0.5)	
  Meningitis  13 (11.0)  58	(10.2)	
  Other or >2  types  7	(5.5)	 27	(4.5)	
Concurrent	condition	data	collected	 96	(75.6)	 448	(75.2)	
	 No	concurrent	conditions	 5	(5.2)	 52	(11.6)	
  1 concurrent condition  34	(35.4)	 142 (31.7) 
  2 concurrent conditions  34	(35.4)	 132	(29.5)	
>3 concurrent conditions  23 (24.0)  122 (27.2) 
Concurrent	condition	types‡	 39	(40.6)	 186	(41.5)	
  Diabetes  26 (27.1)  135	(30.1)	
	 ASCVD	 25	(26.0)	 67	(15.0)	
	 Congestive	heart	failure	 13	(13.5)	 23	(5.1)	
	 Stroke	 15	(15.6)	 37 (8.3) 
	 COPD	 13	(13.5)	 126 (28.1) 
	 Cancer	 44	(45.8)	 195	(43.5)	
Died 11 (8.7)  38 (6.4) 
*LTCF	residents	were	a	median	of	84	years	of	age;	community	residents,	a	median	of	76	years	of	age	(p<0.05).	LTCF,	long-term	care	facility;	GBS,	group	
B	streptococcal;	ASCVD,	atherosclerotic	cardiovascular	disease;	COPD,	chronic	obstructive	pulmonary	disease.	
†A	single	patient	may	have	had	>1	type	of	infection.	
‡Percentages	are	of	those	with	concurrent condition data collected. Streptococcal	Disease	in	the	Elderly
years of age, and a similar study among LTCF residents 
showed a case-fatality rate of 16.7% (7).
Macrolide resistance is common, and increases in clin-
damycin resistance continue to occur among GBS strains. 
In the era of methicillin-resistant Staphylococcus aureus 
infections, nonpenicillin agents, such as clindamycin, are 
increasingly being used for empiric treatment of skin and 
soft tissue infections, but they may not provide adequate 
coverage if these infections are caused by GBS bacteria. 
Although β-lactams remain the preferred therapy for GBS 
infections, strains with elevated penicillin MICs have re-
cently been reported (9–11).
The prevalence of serogroup V in this study is consis-
tent with findings from other studies of adult populations 
(12,13) that show the recent emergence of this serotype. Se-
rotype V has been associated with higher rates of antimicro-
bial drug resistance (14); thus, following trends in serotype 
prevalence may be useful. High rates of antimicrobial drug 
use in the elderly may result in further selection of serotype 
V, and resistance may increase in other serotypes. Molecu-
lar studies may be useful to further evaluate strains because 
serologically nontypeable strains contained specific capsu-
lar polysaccharide genes, including those for V (15). LTCF 
residents  and  persons  with  concurrent  conditions  should 
have high priority for vaccine administration after a vaccine 
becomes available. Vaccines should be multivalent; based 
on predominant serotypes, currently Ia, Ib, II, III, and V; 
and effective and immunogenic for older adults.
Dr Kothari recently completed an Infectious Diseases Fel-
lowship at the University of Minnesota. His research interests 
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Table 2. Susceptibility of invasive GBS disease to erythromycin and clindamycin, Minnesota, 2003–2007* 
No. (%) case-patients 
Susceptibility 
2003 
 (N = 133) 
2004 
(N = 127) 
2005  
(N = 131) 
2006  
(N = 143) 
2007 
 (N = 121)  p value† 
Erythromycin susceptible  95 (71.4)  86 (67.7)  87 (66.4)  90 (62.9)  71 (58.7)  0.023 
Clindamycin susceptible  114 (85.7)  105 (82.7)  108 (82.4)  116 (81.1)  92 (76.0)  0.057 
*GBS, group B streptococcal. 
†Ȥ
2 test for trend. 